Abstract
We here report a non-gene therapy anti-tumor nanoparticles(I3C@cLANPs)based PTEN by loading indole-3-methanol(I3C)into the cross-linked lipoic acid nanoparticles(cLANPs)for triple-negative breast cancer(TNBC)treatment.I3C is a PTEN-specific natural activator while the poor PTEN-activation effi-ciency impedes its ability to achieve the PTEN-mediated tumor therapy.Due to the structural homology of lipoic acid(LA),the cLANPs hold not only LA-like anticancer activity but also PTEN-activation proper-ties,which would synergistically potentiate the PTEN-activation efficiency.The in vitro and in vivo data showed that PTEN expression in the I3C@cLANPs group was 2.1 and 2.8 times higher than that of I3C,respectively.In antitumor evaluation based on the 4T1 tumor-bearing mice showed a tumor inhibitory rate(TIR)of 78.4％at the I3C usage of 20 mg kg-1,54.5％higher than that of I3C alone and 19.7％higher than that of first-line chemotherapy drug Doxorubicin hydrochloride(DOX).Thus,the I3C@cLANPs could address the low activation efficiency in the PTEN-mediated tumor strategy and avoid the risks of gene therapy,holding a good prospect for TNBC and related cancer treatment.
基金项目
国家自然科学基金(22275129)
国家自然科学基金(21975165)
Innovative Research Team Program of Sichuan Province(2021JDTD0015)
Sichuan University postdoctoral interdisciplinary Innovation Fund(2022SCU12106)
NETL
NSTL
万方数据